RNA methyltransferase METTL3 induces intrinsic resistance to gefitinib by combining with MET to regulate PI3K/AKT pathway in lung adenocarcinoma

Clinical research data show that gefitinib greatly improves the progression‐free survival of patients, so it is used in advanced non‐small cell lung cancer patients with EGFR mutation. However, some patients with EGFR sensitive mutations do not have good effects on initial gefitinib treatment, and t...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Fangyan, Wang, Qianqian, Zhang, Chang, Zhang, Chen, Qu, Tianyu, Zhang, Jingya, Wei, Jifu, Guo, Renhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933928/
https://www.ncbi.nlm.nih.gov/pubmed/33491264
http://dx.doi.org/10.1111/jcmm.16114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933928/
https://www.ncbi.nlm.nih.gov/pubmed/33491264
http://dx.doi.org/10.1111/jcmm.16114

Ejemplares similares